The road to replenishment 2016–2020

Seth Berkley, CEO

GAVI Alliance Board meeting
Geneva, Switzerland
18-19 June 2014
Investment opportunity 2016-2020
Sustaining the gains
Accelerate investment now for a sustainable future

GAVI Alliance Board meeting
18-19 June 2014

Cumulative number of graduated countries by end of periods:

<table>
<thead>
<tr>
<th>Period</th>
<th>Number of Countries</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011-15</td>
<td>1</td>
</tr>
<tr>
<td>2016-20</td>
<td>22</td>
</tr>
<tr>
<td>2021-25</td>
<td>29</td>
</tr>
<tr>
<td>2026-30</td>
<td>40</td>
</tr>
</tbody>
</table>
The Ask for 2016–2020: an additional US$ 7.5 billion

Total need: 9.5 bn

The ask: 7.5 bn* (1.5 bn x5)

GAVI needs for 2016-2020

*Through direct contributions and proceeds of new pledges to IFFIm (IFFIm target: <15% ~US$ 1 bn)
Projected impact of resource mobilisation model on donor share of total financing

- **Vaccine co-financing**: 5%
- **Market-shaping**: 14%
- **GAVI donor-funded**: 81%

- **2011-2015**: Share is decreasing
- **2016-2020**: < 60%

- **Vaccine co-financing**: ≈ 15%
  - ≈ 5% graduated
  - ≈ 10% GAVI-supported

- **GAVI Alliance Board meeting**
  - 18-19 June 2014

*compared to 2010 baseline prices*
Accelerating impact 2016-2020

Children immunised

- 2011-2015: 243 million
- 2016-2020: 300 million (+23%)

Future deaths averted

- 2011-2015: 3.9 million
- 2016-2020: 5-6 million (+41%)

Total: 5.5 million
Reaching further:
Closing the immunisation gap - vaccine coverage in GAVI-supported countries by 2020

<table>
<thead>
<tr>
<th>Vaccine Type</th>
<th>Dose</th>
<th>2000</th>
<th>2012</th>
<th>by 2015</th>
<th>by 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Measles-containing vaccine</td>
<td>1st dose</td>
<td>60</td>
<td>76</td>
<td>79</td>
<td>83</td>
</tr>
<tr>
<td>Pentavalent vaccine</td>
<td>3rd dose</td>
<td>43</td>
<td>68</td>
<td>80</td>
<td></td>
</tr>
<tr>
<td>Measles-containing vaccine</td>
<td>2nd dose</td>
<td>32</td>
<td>52</td>
<td>70</td>
<td></td>
</tr>
<tr>
<td>Yellow fever vaccine</td>
<td></td>
<td>8</td>
<td>32</td>
<td>44</td>
<td>69</td>
</tr>
<tr>
<td>Pneumococcal vaccine</td>
<td>3rd dose</td>
<td>9</td>
<td>39</td>
<td>53</td>
<td></td>
</tr>
<tr>
<td>Rotavirus vaccine</td>
<td>last dose</td>
<td>23</td>
<td></td>
<td>70</td>
<td></td>
</tr>
<tr>
<td>Rubella vaccine</td>
<td></td>
<td>17</td>
<td></td>
<td>61</td>
<td></td>
</tr>
<tr>
<td>HPV vaccine</td>
<td>3rd dose</td>
<td>4</td>
<td></td>
<td>37</td>
<td></td>
</tr>
</tbody>
</table>

Coverage by vaccine (%): 2000 2012 by 2015 by 2020

Projections

*a* 2012 coverage estimates are based on country official reported figures.

*b* Target population and coverage estimates are based on 32 yellow fever-endemic GAVI-supported countries in Africa.

*c* Target population for HPV3 is 9-13 year old girls, 2012 coverage estimates derived from SDF projections about scale-up.
The opportunity for further acceleration

greater routine coverage → more children immunised → more lives saved
The opportunity for further acceleration

1% additional increase in coverage per year

150,000 additional lives saved 2016-2020
The risk of under-investment
Under-investment: a potential disproportionate negative impact on girls and women.
Replenishment launch; Off to a good start

- 170+ attendees including 10 ministers, 2 presidents
- Donor feedback: ask is ambitious but achievable
- Announcements:
  - Germany to host pledging conference
  - EC committed 175 million euros over seven years
  - GSK, 5 year price freeze for graduating countries
Strong political leadership for Replenishment

- Strong support in **G7 Summit Declaration**
- Building **domestic support and visibility in** Germany with key stakeholders, civil society and Bundestag
- **Donor to donor peer outreach at the highest levels**
- Discussions underway for **IFFIm replenishment** appreciating important role of long-term financing
- **High-profile advocates**, including 5 African Presidents, Alliance partner leadership, and others (Ban-Ki Moon, Kofi Annan, Donald Kaberuka)
Strong momentum following Brussels meeting

Replenishment launch May
EPI @ 40 and World Health Assembly May
CEO visit to DC to meet Government officials May
Canada MNCH Summit May
Norway signing of IPV agreement June
UK HPV event with First Ladies June
G7 June
GAVI Board June

Q2 2014
Looking ahead: the road to Germany